Testing effectiveness (Phase 2)UnknownNCT04304560
What this trial is testing
Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial
Who this might be right for
Heart Failure With Reduced Ejection Fraction (HFrEF)Diabete Type 2Cardiomyopathies
Damanhour University 60